Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 2/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PARG | Q86W56 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17680243 | 0.82 | BRD4 (0.48) | NSD2BRD4SMN1; SMN2MEN1LMNA | |
| SCHEMBL2803354 | 0.82 | NSD2 (0.58) | NSD2SMN1; SMN2MEN1LMNAKMT2A | |
| SCHEMBL2798389 | 0.81 | LMNA (0.46) | SMN1; SMN2MEN1LMNAKMT2AHPGD | |
| SCHEMBL17680837 | 0.81 | BRD4 (0.47) | NSD2BRD4SMN1; SMN2MEN1LMNA | |
| SCHEMBL19531675 | 0.81 | BRD4 (0.47) | NSD2BRD4SMN1; SMN2MEN1LMNA | |
| SCHEMBL19538961 | 0.78 | BRD4 (0.46) | NSD2BRD4SMN1; SMN2MEN1LMNA | |
| SCHEMBL20746862 | 0.78 | BRD4 (0.46) | NSD2BRD4SMN1; SMN2MEN1LMNA | |
| SCHEMBL19538860 | 0.78 | BRD4 (0.46) | NSD2BRD4SMN1; SMN2MEN1LMNA | |
| SCHEMBL2798321 | 0.77 | NSD2 (0.41) | NSD2BRD4SMN1; SMN2MEN1LMNA | |
| SCHEMBL13232916 | 0.77 | NSD2 (0.41) | NSD2BRD4SMN1; SMN2MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168112-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | RENOVIS, INC. | 2010-07-01 | — | — | US | disclosed |
| EP-1753714-A4 | 2-SUBSTITUTED AND 4-SUBSTITUTED ARYL NITRONE COMPOUDS | RENOVIS INC (US) | 2007-10-17 | — | — | EP | disclosed |
| EP-1753714-A2 | 2-SUBSTITUTED AND 4-SUBSTITUTED ARYL NITRONE COMPOUDS | Renovis, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005079270-A2 | 2-SUBSTITUTED AND 4-SUBSTITUTED ARYL NITRONE COMPOUDS | RENOVIS, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050182060-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | RENOVIS, INC. | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168112-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | CXCR2, CCL5, CCL2 | NSD2 2837/4885BRD4 934/4885SMN1; SMN2 1311/4885 |
| US-20050182060-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | CXCR2, CCL5, CCL2 | NSD2 2837/4885BRD4 934/4885SMN1; SMN2 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.